ClinicalTrials.gg
CompletedNCT00450216Updated Dec 16, 2024Results posted

Efficacy and Safety Study of HZT-501 in Subjects Requiring Nonsteroidal Anti-Inflammatory Drug (NSAID) Treatment

A Phase 3 interventional study of Ibuprofen/famotidine and Ibuprofen in Ulcer, sponsored by Amgen. Completed. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-12-16.

Sponsored by Amgen · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
906
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate whether HZT-501 is effective in reducing the rate of development of ibuprofen-associated ulcers in patients who require long-term daily use of ibuprofen.

Read the detailed description

HZT-501 is a combination product including ibuprofen and the acid reducing agent famotidine. The study is designed to determine whether the combination product reduces the rate of ulcer development in subjects who require long-term daily use of ibuprofen.

Subjects will be assigned randomly, in approximately a 2:1 ratio, to treatment with either HZT-501 (ibuprofen 800 mg/famotidine 26.6 mg) or ibuprofen (800 mg) three times daily for a 24 week treatment period or until they develop either an endoscopically-diagnosed upper gastrointestinal ulcer and/or prohibitive toxicity. Subjects will visit the study center for Screening and at Weeks 4, 8, 16, and 24. Physical exams will be performed, and clinical laboratory measurements made, at selected times during the study. Endoscopic exams will be performed during Screening and at Weeks 8, 16, and 24. Subjects will be contacted four weeks following study completion.

Study with completed results acquired from Horizon in 2024.

02

Conditions studied

  • Ulcer

Keywords

  • ibuprofen
  • famotidine
  • ulcers
  • NSAIDS
  • pain
  • arthritis
  • chronic regional pain syndrome
  • chronic soft tissue pain
  • osteoarthritis
  • rheumatoid arthritis
  • chronic low back pain
03

In context

Ulcer

359 studies on the registry are indexed under Ulcer; 60 are open to participants now.

This study's enrollment of 906 is above the median of 65 across 291 interventional studies indexed under Ulcer.

Browse Ulcer studies →

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Expected to require daily administration of an NSAID for at least the coming six months for conditions such as osteoarthritis, rheumatoid arthritis, chronic low back pain, chronic regional pain syndrome, and chronic soft tissue pain.
  • Did not use a NSAID within the 30 days prior to study entry

Exclusion criteria

Exclusion Criteria:

  • History of erosive esophagitis
  • History of any of the following serious gastrointestinal complications:

    • perforation of ulcers,
    • gastric outlet obstruction due to ulcers, or
    • gastrointestinal bleeding.
  • Active cardiac, renal, and/or hepatic disease
  • Current Helicobacter pylori (H. pylori) infection
  • Use of an acid suppressant agent, misoprostol, or more than 325 mg/day of aspirin within the 14 days prior to study entry.
  • Uncontrolled diabetes
  • Uncontrolled hypertension
  • Positive pregnancy test at screening
  • Positive test at Screening for (HIV), , or .
  • Currently participating, or participation within 30 days prior to study entry, in an drug study

Please note that there are other additional criteria. The study center will determine if patients meet all of the criteria.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
906 participants (actual)

Study arms

  • Experimental
    1

    HZT-501: Ibuprofen 800mg/famotidine 26.6mg

    Drug: Ibuprofen/famotidine

  • Active comparator
    2

    Ibuprofen 800mg

    Drug: Ibuprofen

Interventions

  • DrugIbuprofen/famotidine

    Drug pages: Ibuprofen · Famotidine

    HZT-501: Ibuprofen800mg/famotidine 26.6mg administered orally 3 times daily for 24 weeks

  • Ibuprofen 800mg administered orally 3 times daily for 24 weeks

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Develop Endoscopically-diagnosed Gastric Ulcers

    The primary efficacy endpoint was the number of participants with gastric ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A participant is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed.

    Time frame: 24 weeks

Secondary outcomes

  1. Number of Participants Who Develop Endoscopically-diagnosed Upper Gastrointestinal (UGI) Ulcers During the 24-week Treatment Period.

    The secondary efficacy endpoint was the number of participants with UGI (i.e., gastric and/or duodenal) ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A participant is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed.

    Time frame: 24 weeks

  2. Number of Participants Who Develop Endoscopically-diagnosed Duodenal Ulcers During the 24-week Treatment Period.

    The secondary efficacy endpoint was the number of participants with duodenal ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A participant is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed.

    Time frame: 24 weeks

  3. The Number of Participants Developing Non-steroidal Anti-inflammatory (NSAID)Associated Serious Gastrointestinal Complications (Perforation of Ulcers, Gastric Outlet Obstruction Due to Ulcers, Gastrointestinal Bleeding)

    The secondary efficacy endpoint was the number of participants developing a NSAID-associated serious gastrointestinal complication at any time throughout 24 weeks of treatment. A NSAID-associated serious gastrointestinal complication was defined as a perforation of ulcers, gastric outlet obstruction due to ulcers, and/or gastrointestinal bleeding.

    Time frame: 24 weeks

07

Results

Posted Jun 21, 2011

Participant flow

Participant flow — Overall Study
MilestoneHZT-501Ibuprofen
Started607299
Completed433170
Not completed174129
Withdrew: Adverse event3823
Withdrew: Withdrawal by subject4826
Withdrew: Lost to follow-up169
Withdrew: Upper gastrointestinal (ugi) ulcer5151
Withdrew: Misc2120

Outcome measures

PrimaryNumber of Participants Who Develop Endoscopically-diagnosed Gastric Ulcers

The primary efficacy endpoint was the number of participants with gastric ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A participant is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed.

Time frame:
24 weeks
Reported as:
Number · participants
Number of Participants Who Develop Endoscopically-diagnosed Gastric Ulcers
participantsHZT-501Ibuprofen
Number of Participants Who Develop Endoscopically-diagnosed Gastric Ulcers55 (4.4 to 15.3)52 (4.4 to 15.3)
Statistical analysis
  • HZT-501 vs Ibuprofen · Cochran-Mantel-Haenszel · p = <0.0001 (CMH test stratified by use of low-dose aspirin (yes/no) and prior upper gastrointestinal (UGI) ulcer history (yes/no) at randomization.) · Risk difference (rd): 9.8 · 95% CI 4.4 to 15.3
SecondaryNumber of Participants Who Develop Endoscopically-diagnosed Upper Gastrointestinal (UGI) Ulcers During the 24-week Treatment Period.

The secondary efficacy endpoint was the number of participants with UGI (i.e., gastric and/or duodenal) ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A participant is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed.

Time frame:
24 weeks
Reported as:
Number · participants
Number of Participants Who Develop Endoscopically-diagnosed Upper Gastrointestinal (UGI) Ulcers During the 24-week Treatment Period.
participantsHZT-501Ibuprofen
Number of Participants Who Develop Endoscopically-diagnosed Upper Gastrointestinal (UGI) Ulcers During the 24-week Treatment Period.63 (6.1 to 17.6)61 (6.1 to 17.6)
Statistical analysis
  • HZT-501 vs Ibuprofen · Cochran-Mantel-Haenszel · p = <0.0001 (CMH test stratified by use of low-dose aspirin (yes/no) and prior UGI ulcer history (yes/no) at randomization.) · Risk difference (rd): 11.8 · 95% CI 6.1 to 17.6
SecondaryNumber of Participants Who Develop Endoscopically-diagnosed Duodenal Ulcers During the 24-week Treatment Period.

The secondary efficacy endpoint was the number of participants with duodenal ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A participant is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed.

Time frame:
24 weeks
Reported as:
Number · participants
Number of Participants Who Develop Endoscopically-diagnosed Duodenal Ulcers During the 24-week Treatment Period.
participantsHZT-501Ibuprofen
Number of Participants Who Develop Endoscopically-diagnosed Duodenal Ulcers During the 24-week Treatment Period.8 (1.0 to 6.8)14 (1.0 to 6.8)
Statistical analysis
  • HZT-501 vs Ibuprofen · Cochran-Mantel-Haenszel · p = 0.0006 (CMH test stratified by use of low-dose aspirin (yes/no) and prior UGI ulcer history (yes/no) at randomization.) · Risk difference (rd): 3.8 · 95% CI 1.0 to 6.8
SecondaryThe Number of Participants Developing Non-steroidal Anti-inflammatory (NSAID)Associated Serious Gastrointestinal Complications (Perforation of Ulcers, Gastric Outlet Obstruction Due to Ulcers, Gastrointestinal Bleeding)

The secondary efficacy endpoint was the number of participants developing a NSAID-associated serious gastrointestinal complication at any time throughout 24 weeks of treatment. A NSAID-associated serious gastrointestinal complication was defined as a perforation of ulcers, gastric outlet obstruction due to ulcers, and/or gastrointestinal bleeding.

Time frame:
24 weeks
Reported as:
Number · particpants
The Number of Participants Developing Non-steroidal Anti-inflammatory (NSAID)Associated Serious Gastrointestinal Complications (Perforation of Ulcers, Gastric Outlet Obstruction Due to Ulcers, Gastrointestinal Bleeding)
particpantsHZT-501Ibuprofen
The Number of Participants Developing Non-steroidal Anti-inflammatory (NSAID)Associated Serious Gastrointestinal Complications (Perforation of Ulcers, Gastric Outlet Obstruction Due to Ulcers, Gastrointestinal Bleeding)30

Adverse events

Collected over Randomization to 28 weeks.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HZT-501—22/607 (3.6%)342/607 (56.3%)
Ibuprofen—13/299 (4.3%)184/299 (61.5%)
Most frequent serious events
Showing 10 of 36
Most frequent serious events
EventHZT-501Ibuprofen
cardio-respiratory arrestCardiac disorders0/6072/299
pneumoniaInfections and infestations1/6072/299
renal failure acuteRenal and urinary disorders3/6070/299
benign neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/6071/299
bipolar disorderPsychiatric disorders0/6071/299
bronchitsInfections and infestations0/6071/299
chest painGeneral disorders2/6071/299
coronary artery diseaseCardiac disorders0/6071/299
depressionPsychiatric disorders1/6071/299
drug toxicityInjury, poisoning and procedural complications0/6071/299
Most frequent other events
Showing 10 of 45
Most frequent other events
EventHZT-501Ibuprofen
dyspepsiaGastrointestinal disorders31/60723/299
nauseaGastrointestinal disorders40/60713/299
diarrheaGastrointestinal disorders30/60713/299
constipationGastrointestinal disorders27/60713/299
headacheNervous system disorders23/6079/299
upper respiratory tract infectionInfections and infestations23/60710/299
sinusitisInfections and infestations12/60711/299
hypertensionVascular disorders21/6077/299
abdominal pain upperGastrointestinal disorders20/6077/299
coughRespiratory, thoracic and mediastinal disorders12/6079/299

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)HZT-501IbuprofenTotal
<=18 years000
Between 18 and 65 years500240740
>=65 years10759166
Age, Continuous
Age, Continuous(years)HZT-501IbuprofenTotal
Mean55.5 ± 9.255.9 ± 9.355.6 ± 9.2
Sex: Female, Male
Sex: Female, Male(Participants)HZT-501IbuprofenTotal
Female416208624
Male19191282
Region of Enrollment
Region of Enrollment(participants)HZT-501IbuprofenTotal
United States607299906
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Bello AE, Kent JD, Holt RJ. Gastroprotective efficacy and safety of single-tablet ibuprofen/famotidine vs ibuprofen in older persons. Phys Sportsmed. 2015 Jul;43(3):193-9. doi: 10.1080/00913847.2015.1066229. Epub 2015 Jul 13. PubMed 26165391 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2007, a primary completion of Aug 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2011, 2 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2007
First posted
Mar 22, 2007
Start
Mar 2007
Primary completionActual
Aug 2008
CompletionActual
Oct 2008
Results first posted
Jun 21, 2011
Last update
Dec 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00450216
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Mar 22, 2007
Start date
Mar 2007
Primary completion
Aug 2008
Completion
Oct 2008
Results posted
Jun 21, 2011
Last update
Dec 16, 2024

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ibuprofen · Famotidine

Start the discussion